tacrolimus and Myocarditis

tacrolimus has been researched along with Myocarditis* in 14 studies

Reviews

1 review(s) available for tacrolimus and Myocarditis

ArticleYear
Treatment of the extraintestinal manifestations of inflammatory bowel disease.
    Current gastroenterology reports, 2002, Volume: 4, Issue:6

    There is a paucity of randomized, controlled therapy studies of the extraintestinal manifestations of inflammatory bowel disease (IBD). Most current therapeutic approaches are empiric or based on approaches to therapy in other settings. In the past year anecdotal evidence has emerged for the use of therapies that neutralize tumor necrosis factor-a in both ankylosing spondylitis and the dermatologic extraintestinal manifestations. Topical tacrolimus has also emerged as a potentially useful therapy for dermatologic manifestations. Finally, patients with IBD occasionally become transplant recipients. One study reported worsening IBD after orthotopic liver transplantation for primary sclerosing cholangitis, and another reported the benefit of renal transplantation in amyloidosis-induced renal failure.

    Topics: Antibodies, Monoclonal; Cholangitis, Sclerosing; Dermatitis, Atopic; Drug Combinations; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Infliximab; Myocarditis; Osteoporosis; Psoriasis; Pyoderma Gangrenosum; Tacrolimus; Treatment Outcome; Tumor Necrosis Factor-alpha; Vitamin D

2002

Trials

1 trial(s) available for tacrolimus and Myocarditis

ArticleYear
Acute rejection and heart infection rates in FK 506- versus cyclosporine A-treated heart transplant recipients: an endomyocardial biopsy pathologic study.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 1997, Volume: 16, Issue:9

    Topics: Adult; Aged; Biopsy; Cyclosporine; Endocardium; Female; Follow-Up Studies; Graft Rejection; Heart Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocarditis; Myocardium; Opportunistic Infections; Prospective Studies; Tacrolimus

1997

Other Studies

12 other study(ies) available for tacrolimus and Myocarditis

ArticleYear
Combination Immunosuppressive Therapy for Giant Cell Myocarditis.
    Internal medicine (Tokyo, Japan), 2022, Oct-01, Volume: 61, Issue:19

    A 60-year-old woman with a history of hypothyroidism was referred to our hospital for shortness of breath and a left ventricular ejection fraction (LVEF) of 13%, which required continuous dobutamine injection with intra-aortic balloon pump support. An endomyocardial biopsy obtained from the right ventricle revealed an infiltration of giant cells and eosinophils, indicating giant cell myocarditis. In addition to heart failure treatment, combined immunotherapy with steroids, tacrolimus, and intravenous immunoglobulin was administered. Transthoracic echocardiography demonstrated a dramatic improvement in the LVEF after this therapy, and the patient was discharged home without symptoms on day 72.

    Topics: Dobutamine; Female; Giant Cells; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Immunosuppressive Agents; Middle Aged; Myocarditis; Stroke Volume; Tacrolimus; Ventricular Function, Left

2022
Targeted Therapy for Acute Autoimmune Myocarditis with Nano-Sized Liposomal FK506 in Rats.
    PloS one, 2016, Volume: 11, Issue:8

    Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the need to develop a more effective therapeutic approach remains. Nano-sized liposomes may accumulate in and selectively deliver drugs to an inflammatory lesion with enhanced vascular permeability. The aims of this study were to investigate the distribution of liposomal FK506, an immunosuppressive drug encapsulated within liposomes, and the drug's effects on cardiac function in a rat experimental autoimmune myocarditis (EAM) model. We prepared polyethylene glycol-modified liposomal FK506 (mean diameter: 109.5 ± 4.4 nm). We induced EAM by immunization with porcine myosin and assessed the tissue distribution of the nano-sized beads and liposomal FK506 in this model. After liposomal or free FK506 was administered on days 14 and 17 after immunization, the cytokine expression in the rat hearts along with the histological findings and hemodynamic parameters were determined on day 21. Ex vivo fluorescent imaging revealed that intravenously administered fluorescent-labeled nano-sized beads had accumulated in myocarditic but not normal hearts on day 14 after immunization and thereafter. Compared to the administration of free FK506, FK506 levels were increased in both the plasma and hearts of EAM rats when liposomal FK506 was administered. The administration of liposomal FK506 markedly suppressed the expression of cytokines, such as interferon-γ and tumor necrosis factor-α, and reduced inflammation and fibrosis in the myocardium on day 21 compared to free FK506. The administration of liposomal FK506 also markedly ameliorated cardiac dysfunction on day 21 compared to free FK506. Nano-sized liposomes may be a promising drug delivery system for targeting myocarditic hearts with cardioprotective agents.

    Topics: Acute Disease; Animals; Autoimmune Diseases; Cytokines; Disease Models, Animal; Immunosuppressive Agents; Liposomes; Male; Myocarditis; Nanoparticles; Rats; Rats, Inbred Lew; Tacrolimus

2016
Polymyositis and myocarditis after donor lymphocyte infusion.
    International journal of hematology, 2009, Volume: 90, Issue:1

    Chronic graft versus host disease (GVHD) is a common late complication of hematopoietic stem cell transplantation. Polymyositis is a rare manifestation of chronic GVHD after donor lymphocyte infusion (DLI). Patients with both polymyositis and myocarditis have not been reported to date. Here, we report an 18-year-old female patient who developed polymyositis and myocarditis after a DLI. The patient developed the symptoms of fever, generalized myalgia, dysarthria, and asymptomatic sinus tachycardia at DLI day +102, and 17 days after the discontinuation of immunosuppressants. The laboratory testing showed elevated muscle enzymes, and the electromyographic examination revealed myopathic abnormalities compatible with the diagnosis of myositis. The muscle biopsy showed CD8+ T cell infiltration of the muscle fibers. The electrocardiogram (ECG) showed sinus tachycardia with an incomplete right bundle branch block, anteroseptal ST elevation and lateral ST depression. Echocardiography showed mild hypokinesia of the left interventricular septal wall without evidence of infection or leukemic relapse. The patient was immediately treated with 60 mg/day of prednisone and tacrolimus after the diagnosis of polymyositis and myocarditis, apparently associated with chronic GVHD. The cardiac and muscle enzymes decreased and the ECG normalized after immunosuppressant treatment. The follow-up ECG 2 weeks after initiation of therapy was normal.

    Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents; Blood Donors; Chronic Disease; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Lymphocyte Transfusion; Myocarditis; Polymyositis; Prednisone; Tacrolimus

2009
A case report of giant cell myocarditis and myositis observed during the clinical course of invasive thymoma associated with myasthenia gravis.
    The Keio journal of medicine, 2004, Volume: 53, Issue:1

    The patient is a 62-year-old man who was diagnosed with myasthenia gravis and invasive thymoma at the age of 45 years, and had received treatment by extended thymectomy and radiotherapy. At the age of 61, he had suffered from a myasthenic crisis, and been administered immunoadsorption therapy under managed ventilatory care. Treatment had then been continued with steroids; however, due to subsequent deterioration of his diabetic state, treatment was switched to the immunosuppressant drug tacrolimus. Three months after the commencement of tacrolimus administration, the patient developed generalized malaise and dyspnea. The serum creatine phosphokinase (CPK) level was abnormally elevated, and abnormal electrocardiographic findings were noted, including atrioventricular dissociation and ventricular escape contraction. Steroid pulse therapy was therefore initiated, however, 4 days later, the patient suddenly died. Autopsy examination revealed inflammatory cell infiltration with giant cells in the myocardium, diffuse myocardial degeneration, and polymyositis. The case was therefore considered as one with the syndrome of myasthenia gravis, polymyositis, giant cell myocarditis, and thymoma.

    Topics: Alopecia; Creatine Kinase; Dyspnea; Electrocardiography; Giant Cells; Humans; Immunosuppressive Agents; Male; Middle Aged; Myasthenia Gravis; Myocarditis; Myocardium; Myositis; Polymyositis; Radiography, Thoracic; Tacrolimus; Thymoma; Thymus Neoplasms; Time Factors; Treatment Outcome

2004
FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes.
    Journal of cardiovascular pharmacology, 2000, Volume: 35, Issue:3

    FTY720 is a new immunosuppressant agent and selectively decreases the number of circulating lymphocytes. In this study, we compared the effects of FTY720 with those of tacrolimus on experimental autoimmune myocarditis (EAM) in rats. A significant decrease in circulating lymphocyte counts was noted after a single administration of FTY720 in normal rats. At day 0, 7-week-old male Lewis rats were immunized with purified porcine cardiac myosin emulsified in complete Freund's adjuvant. FTY720 or tacrolimus was administered intraperitoneally daily. The number of myocarditis-affected areas in the FTY720 treatment groups with doses of 0.1 mg/kg/ day was significantly lower than those in control groups at days 14 and 28. In addition, at day 28, the myocarditis-affected areas in the FTY720 treatment group were significantly smaller than those in the tacrolimus treatment group receiving the same dose. Effects of early administration (days 0-10) and delayed administration (days 11-20) of FTY720 also were examined. At day 28, the myocarditis-affected areas in the early therapy group were significantly lower than those in the control group. In conclusion, we demonstrated that the development of EAM could be prevented by FTY720. These data also indicated that lymphocyte-mediated immunity is critically involved in the development of EAM.

    Topics: Analysis of Variance; Animals; Autoimmune Diseases; Body Weight; Fingolimod Hydrochloride; Immunosuppressive Agents; Injections, Intraperitoneal; Lymphocyte Count; Lymphocytes; Male; Myocarditis; Organ Size; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine; Tacrolimus

2000
Synergistic effects of tacrolimus and human interferon-alpha A/D in murine viral myocarditis.
    The Journal of pharmacology and experimental therapeutics, 1995, Volume: 274, Issue:1

    The effects of interferon-alpha A/D (IFN) therapy in combination with various immunosuppressants were investigated in a murine model of viral myocarditis. Viral infection is an important cause of morbidity in immunocompromised hosts and transplant recipients. Human IFN therapy reduces viral replication, reducing the virus-induced myocardial destruction. Groups consisting of 25 C3H/He mice received i.p. injections of prednisolone, azathioprine, 15-deoxyspergualin, cyclosporine or tacrolimus (FK506), for 16 days beginning 2 days before inoculation with 500 plaque-forming units of encephalomyocarditis virus (EMCV). IFN, 10(4) U/g daily, was administered i.p. alone or in combination with immunosuppressants to separate groups of mice beginning on the day of viral inoculation. Animals were sacrificed at random at 4 or 10 days after inoculation with EMCV. The survival rate was significantly higher in mice treated with azathioprine, 15-deoxyspergualin, cyclosporine or FK506 in combination with IFN than in infected controls (P < .01) and was similar to the rate in the IFN monotherapy group. Survival in mice treated with prednisolone resembled that in infected controls and was significantly lower than in mice treated with IFN (P < .01). Heart weight was lower and cellular infiltration in the myocardium was reduced in mice treated with both FK506 and IFN compared with mice given IFN monotherapy. The results suggest that the effect of IFN therapy in viral myocarditis differs depending on which immunosuppressants is used. The findings suggest that the combination of FK506 and IFN may have beneficial effects in hosts with viral myocarditis by reducing cellular infiltration of heart.

    Topics: Animals; Antiviral Agents; Body Weight; Cardiovirus Infections; Drug Synergism; Encephalomyocarditis virus; Female; Humans; Interferon Type I; Interferon-alpha; Mice; Mice, Inbred C3H; Myocarditis; Myocardium; Organ Size; Recombinant Fusion Proteins; Recombinant Proteins; Tacrolimus

1995
FK506 therapy of experimental autoimmune myocarditis after onset of the disease.
    American heart journal, 1993, Volume: 126, Issue:6

    Preventive effects of FK506 on autoimmune myocarditis have been demonstrated, but the therapeutic efficacy of the agent in established myocarditis yet remains to be assessed. In this study, effects of FK506 on experimental autoimmune myocarditis were investigated by the use of the agent after the onset of the disease. Lewis rats were immunized with either cardiac myosin or bovine serum albumin (BSA) in complete Freund's adjuvant. The onset of the disease was ascertained by examining randomly chosen cardiac myosin-immunized rats. Animals were divided into four groups: the BSA-immunized saline-treated group (group A, n = 6); the BSA-immunized FK506-treated group (group B, n = 6); the myosin-immunized saline-treated group (group C, n = 6); and the myosin-immunized FK506-treated group (group D, n = 11). Saline or 1.0 mg/kg/day of FK506 were intramuscularly injected from day 16 to day 27. All the rats were put to death on day 28. Rats of group C became severely ill by the third week, while in contrast, rats of group D remained active, as did rats of groups A and B. The heart weight/body weight ratio was significantly lower in group D than in group C rats. Group mean values were 3.48 +/- 0.10 gm/kg for group A, 3.48 +/- 0.16 gm/kg for group B, 4.94 +/- 0.66 gm/kg for group C, and 3.88 +/- 0.43 gm/kg for group D. Rats of group C showed severe myocarditis with mononuclear cell infiltration, myocardial necrosis, and interstitial edema.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: Animals; Autoimmune Diseases; Body Weight; Heart; Myocarditis; Myocardium; Organ Size; Random Allocation; Rats; Rats, Inbred Lew; Tacrolimus

1993
Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis.
    Clinical immunology and immunopathology, 1993, Volume: 68, Issue:2

    Topics: Animals; Antigens, Viral; Coxsackievirus Infections; Enterovirus B, Human; Immunosuppressive Agents; Interferon-gamma; Male; Mice; Mice, Inbred Strains; Mice, SCID; Myocarditis; Tacrolimus; Time Factors

1993
An immunosuppressant compound, FK-506, prevents the progression of autoimmune myocarditis in rats.
    Clinical immunology and immunopathology, 1992, Volume: 62, Issue:3

    A new immunosuppressive compound, FK-506, is a macrolide produced by Streptomyces tsukubaensis. It is reported that FK-506 prolongs the viability of allogenic grafts of the heart and kidney in vivo and inhibits the development of autoimmune diseases. Furthermore, immunosuppressive therapy of myocarditis in humans has been given special attention by various observers; however, it is controversial. This study investigates the effects of FK-506 on experimental autoimmune myocarditis in rats. We performed two experiments. In Experiment 1, FK-506 was given intramuscularly on Days 11-20 after the first immunization. The rats were immunized twice (on Day 0 and Day 7). They were injected subcutaneously in the footpads with 1.0 mg of human cardiac myosin in equal volumes of complete Freund's adjuvant supplemented with Mycobacterium tuberculosis. They were divided into four groups: Control (six rats, saline), group 1 (six rats, FK-506: 0.1 mg/kg/day), group 2 (seven rats, FK-506: 0.32 mg/kg/day), and group 3 (six rats, FK-506: 1.0 mg/kg/day). To investigate the histologic extent of myocarditis, we formulated a histologic score (0-3). Histologic scores were: Control, 1.90 +/- 0.14; group 1, 0.97 +/- 0.46; group 2, 0.03 +/- 0.05; and group 3, 0 +/- 0. The indices of heart weight/body weight were: Control, 0.74 +/- 0.10%; group 1, 0.45 +/- 0.05%; group 2, 0.35 +/- 0.03%; and group 3, 0.35 +/- 0.03%. In Experiment 2, FK-506 was given on Days 1-10 after the first immunization, earlier than in Experiment 1. The rats were similarly divided into four groups. Each group was given the same dose of FK-506 as in Experiment 1. Histologic scores were: Control 1.49 +/- 0.24; group 1, 1.60 +/- 0.22; group 2, 0.29 +/- 0.41; and group 3, 0.03 +/- 0.03. The indices of heart weight/body weight were: Control, 0.69 +/- 0.15%; group 1, 0.76 +/- 0.09%; group 2, 0.42 +/- 0.08%; and group 3, 0.37 +/- 0.03%. Accordingly, in Experiments 1 and 2, the effects of FK-506 on autoimmune myocarditis were dose-dependent. On the other hand, in Experiments 1 and 2, not only in the control group but also in all treated groups, the titers of anti-myosin IgG were high. In conclusion, even if it is administered just before the onset of myocarditis, FK-506 is extremely effective at suppressing autoimmune myocarditis, despite a high titer of anti-myosin IgG.

    Topics: Animals; Antibodies; Autoimmune Diseases; Body Weight; Male; Myocarditis; Myosins; Organ Size; Rats; Rats, Inbred Lew; Tacrolimus

1992
The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.
    The Journal of pharmacology and experimental therapeutics, 1992, Volume: 260, Issue:3

    To test the therapeutic efficacy of immunosuppression with FK-506 upon coxsackievirus B3 myocarditis, C3H/He mice were inoculated with coxsackievirus B3, and the effects of FK-506 were compared to those of cyclosporine. FK-506 (2.5 mg/kg/day) or cyclosporine (25 mg/kg/day) was administered s.c. daily on days 0 to 14 (experiment I) and on days 14 to 28 (experiment II). In experiment I, the survival rate of the FK-506 or cyclosporine-treated group was significantly lower compared with that of the untreated, control group. However, the score of myocardial cellular infiltration in both treated groups was lower compared to the control. On day 14, myocardial virus was not detected in the control group, but was present in both treated groups. Serum neutralizing antibody titers on day 14 in FK-506 group were lower than in the control group. In experiment II, survival rate did not differ significantly among the three groups. Serum-neutralizing antibody titers on day 21 in FK-506 group were lower than in the control. Histologically, marked cellular depletion in the thymus and spleen was evident in FK-506 groups; in cyclosporine groups, it was only evident in the thymus. Thus, FK-506 induced immunosuppression in coxsackievirus B3 myocarditis, associated with a high mortality, notwithstanding the reduction of myocardial cellular infiltration in the acute stage when immune mechanisms play a role in the pathogenesis of the disease. With respect to the dosage, the immunosuppressive action of FK-506 in vivo is at least 10-fold stronger compared to that of cyclosporine.

    Topics: Animals; Antibodies, Viral; Coxsackievirus Infections; Enterovirus B, Human; Male; Mice; Mice, Inbred C3H; Myocarditis; Myocardium; Tacrolimus

1992
Impact of FK 506 on myocarditis in the enteroviral murine model.
    Transplantation proceedings, 1991, Volume: 23, Issue:6

    Topics: Animals; Coxsackievirus Infections; Enterovirus B, Human; Heart; Interferon-gamma; Male; Mice; Mice, Inbred A; Myocarditis; Myocardium; Recombinant Proteins; Tacrolimus

1991
FK 506 and orthotopic liver transplantation in the rat.
    Transplantation proceedings, 1990, Volume: 22, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Graft Survival; Immunosuppressive Agents; Liver Transplantation; Male; Myocarditis; Rats; Rats, Inbred Strains; Tacrolimus

1990